Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection

Journal of Urology

Volumn 172, Issue 3, 2004, Pages 900-904

  Canto, Eduardo I ^a   Singh, Herb ^a   Shariat, Shahrokh F ^c   Kadmon, Dov ^a   Miles, Brian J ^a   Wheeler, Thomas M ^a,b   Slawin, Kevin M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biopsy; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PERCENT FREE PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SEXTANT BIOPSY; PROSTATE TWELVE CORE BIOPSY; RECEIVER OPERATING CHARACTERISTIC; TECHNIQUE;

EID: 4143121190     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000134619.72675.8d     Document Type: Article

References (12)

1. Gann, P. H., Ma, J., Catalona, W. J. and Stampfer, M. J.: Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol, 167: 2427, 2002
2. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A. et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279: 1542, 1998
3. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 274: 1214, 1995
4. Gore, J. L., Shariat, S. F., Miles, B. J., Kadmon, D., Jiang, N., Wheeler, T. M. et al: Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol, 165: 1554, 2001
5. Presti, J. C., Jr., O'Dowd, G. J., Miller, M. C., Mattu, R. and Veltri, R. W.: Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol, 169: 125, 2003
6. Roehl, K. A., Antenor, J. A. V. and Catalona, W. J.: Serial biopsy results in prostate cancer screening study. J Urol, 167: 2435, 2002
7. Chan, T. Y., Chan, D. Y., Lecksell, K., Stutzman, R. E. and Epstein, J. I.: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol, 166: 2181, 2001
8. Taylor, J. A., 3rd, Gancarczyk, K. J., Fant, G. V. and McLeod, D. G.: Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology, 60: 841, 2002
9. Singh, H., Canto, E. I., Shariat, S. F., Kadmon, D., Miles, B. J., Wheeler, T. M. et al: Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol, 171: 1089, 2003
10. Singh, H., Canto, E. I., Shariat, S. F., Kadmon, D., Miles, B. J., Wheeler, T. M. et al: Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol, 171: 204, 2003
11. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 271: 368, 1994
12. Roehrborn, C. G., Pickens, G. J. and Sanders, J. S.: Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology, 47: 347, 1996